ddp4 and glp 1 Mechanism of action for GIP, GLP-1 analogues DPP4 inhibitors in Frontiers | Clinical Use of
Description
Giugliano, D
Treatment starts at 0.25 mg weekly for four weeks to improve tolerability, then typically increases to 0.5 mg, with further escalation to 1 mg or 2 mg if needed
As most discontinuations occurred during the rapid dose-escalation period of treatment, slower up-titration of dose may counter these
Consistent dosing matters more than injection temperature
Have serious metabolic health conditions: If you have been diagnosed with type 2 diabetes, metabolic syndrome, or other significant metabolic conditions, these require medical management
After treatment initiation, anticipate gradual weight loss coupled with lifestyle adjustments for optimal results and sustained health benefits
